Filing Flows › Maravai Lifesciences Holdings (MRVI) › Q2 2026 › vs Q1 2026
Maravai Lifesciences Holdings (MRVI) Q2 2026 vs Q1 2026 (quarter over quarter)
Maravai Lifesciences Holdings's revenue fell $14.4M (-22%) from $65.8M in Q1 2026 to $51.4M in Q2 2026.
Maravai Lifesciences Holdings, Q2 2026: revenue $51.4M (+8% year over year), operating margin -29.3%, net loss $21.6M, operating cash flow $4.0M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 7.0% | 6.4% | +0.6 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $51.4M | $65.8M | −$14.4M | -22% |
| Income tax benefit | $171K | $151K | $20K | +13% |
| Net loss | $21.6M | $6.4M | $15.3M | +239% |
| Costs & expenses | $73.2M | $72.4M | $879K | +1% |
| Operating costs | $66.5M | $68.0M | −$1.5M | -2% |
| Interest & other, net | $6.7M | $4.4M | $2.3M | +54% |
| Cost of revenue | $30.8M | $32.1M | −$1.3M | -4% |
| Research & development | $3.7M | $3.9M | −$187K | -5% |
| SG&A | $32.1M | $29.1M | $3.0M | +10% |
| Operating cash sources | $25.6M | $15.0M | $10.6M | +70% |
| Depreciation & amortization | $11.8M | $11.4M | $410K | +4% |
| Share-based compensation | $10.2M | $6.7M | $3.5M | +51% |
| Working capital & other | $3.6M | −$3.1M | $6.7M | — |
| Net loss absorbed | $21.6M | $6.4M | $15.3M | +239% |
| Operating cash flow | $4.0M | $8.7M | −$4.7M | -54% |
| Free cash flow (OCF − capex) | $3.6M | $4.2M | −$606K | -14% |
| Capital expenditures | $370K | $4.4M | −$4.1M | -92% |
Questions
How much did Maravai Lifesciences Holdings's revenue grow quarter over quarter in Q2 2026?
Maravai Lifesciences Holdings's revenue fell $14.4M (-22%) from $65.8M in Q1 2026 to $51.4M in Q2 2026.